Moderna (MRNA) Faces Multiple Regulatory Challenges
On May 31, Bloomberg reported that the FDA recently granted Moderna Inc. (NASDAQ:MRNA) a narrower approval for its next-generation COVID-19 vaccine.
Moderna Inc. (MRNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Theleme Partners Patrick Degorce | 7,242,390 | $205,321,756 | -1% | 16.14% |
| 2. | D E Shaw D. E. Shaw | 5,636,151 | $159,784,881 | +219% | 0.14% |
| 3. | 4,895,300 | $138,781,755 | +44% | 0.03% | |
| 4. | 3,931,400 | $111,455,190 | +15% | 0.02% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 3,808,500 | $107,970,975 | +3573% | 0.24% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.53 | 57,493 | Officer, Director | 9,210,686 | 2025-03-03 | Filing | |
| $31.04 | 102,821 | Officer, Director | 9,153,193 | 2025-03-03 | Filing | |
| $31.76 | 31,620 | Director | 312,027 | 2025-03-03 | Filing | |
| $19.00 | 52,631 | Director | 420,407 | 2020-02-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.00 | 312 | Director | 580 | 2025-06-11 | Filing | |
| $44.68 | 529 | Officer | 20,446 | 2024-12-09 | Filing | |
| $43.30 | 112 | Officer | 19,837 | 2024-12-03 | Filing | |
| $43.30 | 314 | Officer | 1,443,904 | 2024-12-03 | Filing | |
| $42.79 | 1,420 | Officer | 11,066 | 2024-11-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 40,396,513 | $1,145,241,144 | 0.02% | |
| 2. | 27,181,154 | $770,585,733 | 0.02% | |
| 3. | 24,948,558 | $707,291,620 | 0.62% | |
| 4. | 21,130,029 | $599,036,329 | 0.04% | |
| 5. | 17,778,558 | $504,022,119 | 0.02% |
News See All
Jim Cramer on Moderna (MRNA): “I’ve Been Against This Stock For So Long”
We recently published a list of Jim Cramer Talked About These 13 Stocks. In this article, we are going to take a look at where Moderna, Inc.
Jim Cramer Talked About These 13 Stocks
“If you want to know what makes a successful retailer, all you have to do is read the conference calls. Everything's on display, no secret sauces. I'm always telling you to read these transcripts.
Moderna, Inc. (MRNA) Submits Updated COVID Vaccine for Regulatory Review
The revised version of the vaccine, marketed as Spikevax, follows FDA guidance recommending that this year’s shots target variants from the JN.1 lineage, specifically favoring the LP.8.1 strain.
Why Moderna, Inc. (MRNA) Crashed Today
We recently published a list of 10 Firms Drenched in Red Today.
Why Moderna, Inc. (MRNA) Skyrocketed Today
We recently published a list of These 10 Firms Just Beat the Market Today.
Moderna Leads S&P 500 After FDA Eases Booster Concerns
Moderna, Inc. (NASDAQ:MRNA) shares soared to the top of the S&P 500 gainers in early afternoon trading on May 20, surging by 11%. The rise followed the U.S.
Why Moderna, Inc. (MRNA) Surged Today
We recently published a list of 10 Stocks That Stole the Show Today.
Billionaire Hedge Funds
